NCT07117227Recruiting
Validation of RCC Predicting Model With Emulated-target Trial
Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 4700 (estimated)
- First submitted
- 22 Jul 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Peking University Third Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT07117227
What you commit to
- Study type: Observational
- Planned participants: 4700
- From 1 Sept 2025 to the primary completion date, 1 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of other malignant tumors.
Other
- Subjects with severely missing clinical information;
- Recurrence observed before first postoperative follow-up.
- Discontinue the adjuvant treatment within in the first two course because of severe adverse react.
Who the study is looking for
- Adults ≥18 years of age;
- Diagnosis of primary renal cell carcinoma before and during the surgery;
- Received radical nephrectomy/nephron-sparing surgery.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Third Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.